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In 1971, the JC virus (JCV) was isolated from the brain of a 
patient with Hodgkin’s disease who died of progressive 
multifocal leukoencephalopathy (PML).1 In that moment, 
the disease was named “JC virus” after the patient’s initials,1 
and classical PML was described as a condition presenting 
in patients with neurological symptoms associated with 
nonenhancing focal lesions, preferentially in white matter, 
with a positive result for JCV detected in brain tissue by 
polymerase chain reaction (PCR).2 
Before 1980, PML was a very rare disease, a “back of the 
textbooks” condition.3 With immunossupression caused 
by HIV infection, JCV reactivation occurred, and with AIDS 
epidemics, an increased frequency of classic PML was seen. 
Not only more patients presented with classic PML, but novel 
manifestations of PML were described in patients presenting 
with AIDS-related PML, such as gray matter involvement and 
symmetrical lesions in brain magnetic resonance imaging 
(MRI).2 With the development of highly active antiretroviral 
therapy (HAART), an additional new form of PML was 
described, named “inflammatory PML”, as a part of immune 
reconstitution inflammatory syndrome (IRIS). In this new 
description, different from classic PML  (where brain lesions are 
demyelinating nonenhancing after contrast infusion), patients 
experience worsening of neurological condition after initiating 
HAART, a consequence of inflammation and edema of cerebral 
parenchyma. This can be radiologically translated as brain 
edema, mass effect and contrast enhancement.2 Despite the 
improvement in immunological recovery consequent to the 
spreading HAART use, PML frequency has not decreased to the 
extent of other opportunistic infections.3
Finally, more recently, JCV was linked with cerebellar 
syndrome in HIV infected patients.4 Besides the fact that, 
traditionally, JCV causes supratentorial disease, some patients 
presented with cerebellar syndrome with image showing 
isolated atrophy. In 1998, a syndrome of degeneration of the 
cerebellum in HIV-infected patients was described, one of 
whom had JCV detected by PCR in cerebellar tissue biopsy. 
The authors proposed the possibility of latent JCV infection 
of cerebellar granular cells in HIV-infected patients with 
cerebellar atrophy, lacking further evidence of other features 
of PML. 
Later, in 2005, Koralnik et al.5 described a case of JCV 
granule cell neuronopathy in a patient with JCV-associated 
cerebellar degeneration with isolated cerebellar symptoms. 
MRI showed diffuse cerebellar atrophy and occasional white 
matter abnormalities within the cerebellum. The disease 
was confirmed when immunohistochemistry demonstrated 
preservation of Purkinje cells, and in situ PCR revealed 
selective depletion of cerebellar granule cells and JCV infection 
of granule cell neurons. Thus, the third form of JCV encephalic 
disease was described as JCV granule cell neuronopathy.
In this issue of BJID, Piza et al.6 analysed retrospectively 
patients presenting with PML over a five-year period of admissions 
at the Emilio Ribas Institute (São Paulo – Brazil). Forty-seven cases 
were described and the newer forms of PML were observed, such 
as inflammatory PML (three patients, 6%) and JCV granule cell 
neuronopathy (four patients, 9%). Mortality of patients presenting 
PML was also studied. In one year of follow-up, with available 
data from 39 of the 47 patients, the study showed 54% mortality, 
mostly in-hospital deaths. Overall mortality was high (54% of 39 
patients with available data within 1 year of follow-up).
This article shows that newer (or unveiled?) forms of JCV 
infection also occur in Brazil, and there is a need for high 
suspicion by infectious diseases specialists to detect these 
syndromes and order specific tests. Unfortunately, JCV news 
are not all good. More than 40 years later, treatment of AIDS-
related PML relies only on optimized HAART, and there is no 
specific treatment showing good results.3 Diagnostic criteria 
for PML must be reviewed now that novel syndromes and 
more cases of clinically defined PML lacking JCV positive PCR 
have been described, a fact that may be related to less severe 
immunossupression seen in many HIV patients nowadays.3
More than 40 years later, PML is still a hit, with newer 
related syndromes and continuing debate of proper treatment 
and best way of diagnosis.
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